18:25 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Alopexx reports Phase I data for bacterial infection prevention candidate

In October, Alopexx Vaccine LLC (Concord, Mass.) reported data from a Phase I trial in 16 healthy volunteers showing that 75-150 μg doses of bacterial infection prevention candidate AV0328 were well tolerated. Alopexx said the...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Ixodes scapularis antifreeze glycoprotein (iafgp); poly-N-acetyl glucosamine (PNAG) Rodent, fruit fly and cell culture studies suggest iafgp derived from the I. scapularis...
07:00 , Jun 13, 2013 |  BC Innovations  |  Targets & Mechanisms

Table 2: Nine out of ten for PNAG

broadening infection protection: Table 2: Nine out of ten for PNAG...
07:00 , Jun 13, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection; candidiasis; malaria Poly-N-acetylglucosamine (PNAG) In vitro and mouse studies suggest an anti-PNAG antibody could help prevent infections from...
07:00 , Jun 13, 2013 |  BC Innovations  |  Targets & Mechanisms

PNAG: broadening infection protection

A multi-institutional team has added more than 20 pathogens to the list of known bacteria that express poly- N -acetylglucosamine, a bacterial capsule polysaccharide that provides a potentially broad-spectrum target for vaccination. 1 The findings...